JB-101

N/A

Report date: 2024/03/29 20:06:02

Base Information

Drug NameJB-101

Drug Alias NameJB-101

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Induced T cell therapy

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsRejection of liver transplantation

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesJuntendo University

China Registration ClassN/A

Develop Information

Active CompaniesAlliedCel Corp JUNTEN BIO Co Ltd Juntendo University

Inactive CompaniesN/A

Active IndicationsRejection of liver transplantation

Inactive IndicationsN/A

Other Information

ATC CodeN/A